Aetna Inc. and its subsidiary companies are not responsible or liable for the content, accuracy, or privacy practices of linked sites, or for products or services described on these sites. This was a double-blind randomized trial of 265 subjects with resistant hypertension implanted and subsequently randomized (2:1) 1 month after implantation. Implantable device therapy for the treatment of resistant hypertension. Copyright Aetna Inc. All rights reserved. The authors concluded that the findings of the current study demonstrated that MSCS treatment can lower the arterial pressure in normotensive rabbits. 2007;33(4):414-421. All complications resolved without sequelae. This latter peculiarity has implemented the research for new approaches to the treatment of the disease. Ann Vasc Surg. These investigators monitored finger and brachial BP, HR, and MSNA. In severe cases of Carotid Sinus Hypersensitivity or Carotid Sinus Syndrome, there is loss of consciousness or seizures that may occur due to buildup of pressure in the carotid sinus arteries as a result of manual stimulation. Hypertension. The early study results using baroreflex ES therapy are promising and suggest that it may play a significant role in controlling BP in the future. .strikeThrough { The authors concluded that this was the first study demonstrating a significant BP reduction in ABPM in patients undergoing chronically stimulation of the carotid sinus using the BAT neo device. color: #FFF; The CSLs are placed on the carotid arteries and run subcutaneously to the pulse generator (Note: the procedure does not involve carotid dissection). J Am Coll Cardiol. list-style-type: decimal; Ng and colleagues (2016) discussed 7 novel devices for the treatment of resistant hypertension (RHTN). Links to various non-Aetna sites are provided for your convenience only. Jordan et al (2013) stated that hypertension is the primary risk factor for cardiovascular and renal-disease endpoints. The authors concluded that BAT may be a promising therapy for HFpEF and introduced the HOPE4HF trial, a randomized outcomes trial designed to evaluate the clinical safety and effectiveness of BAT in the HFpEF population. New devices in heart failure: An European Heart Rhythm Association report: Developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association. Additional comments: To ensure the quality of comments, you need to be connected. by which electric carotid sinus field stimulation affects blood pressure in human subjects are unknown. Carotid sinus stimulation. It decreases the sympathetic activity and inhibits the renin system, which results in reduced blood pressure and heart rate. Zhang J, Zhou S, Xu G. Carotid baroreceptor stimulation: A potential solution for resistant hypertension. Smaller coils of 50 mm diameters have been used in rats for research. Lovett EG, Schafer J, Kaufman CL. OL OL LI { In the BAT group versus the control group, QOL score decreased (Δ = -14.1; 95 % confidence interval [CI]: -19 to -9; p < 0.001), 6MHW distance increased (Δ = 60 m; 95 % CI: 40 to 80 m; p < 0.001), NT-proBNP decreased (Δ = -25 %; 95 % CI: -38 % to -9 %; p = 0.004), and the MANCE-free rate was 97 % (95 % CI: 93 % to 100 %; p < 0.001). }. These investigators reported on the first 17 patients enrolled in a multi-center study. Despite an initial drawback in a RCT of bilateral carotid sinus stimulation (CSS), new and less invasive and unilateral systems for BAT with the BAROSTIM NEO have been developed which show promising results in small non-RCTs. Curr Hypertens Rep. 2017;19(7):59. The Rheos Baroreflex Hypertension Therapy System (CVRx, Inc., Minneapolis, MN) is an implantable device for the treatment of patients with drug-resistant hypertension (i.e., the hypertensive state characterized by the inability of multiple anti-hypertensive drug interventions to lower BP to goal levels) who have a systolic BP (SBP) of greater than or equal to 160 mm Hg. 4. Moreover, these researcher stated that further studies are needed to examine the impact of BAT on the frequency of hospitalization and mortality, and identify patients with HFrEF most likely to gain lasting benefit from this type of intervention. 2011;19(2):52-75. Grassi G, Quarti-Trevano F, Brambilla G, Seravalle G. Blood pressure control in resistant hypertension: New therapeutic options. The spectrum of therapeutic impact suggests that Rheos therapy may improve long-term outcomes in drug-resistant hypertension and possibly benefit related populations. Other potential benefits include regression of left ventricular hypertrophy, normalization of the sympatho-vagal balance, inhibition of the renin-angiotensin-aldosterone system, arterio- and veno-dilation, and preservation of renal function.